APA (7th ed.) Citation
(2026). Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology.
Chicago Style (17th ed.) Citation
"Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration." Clinical Ophthalmology 2026.
MLA (9th ed.) Citation
"Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration." Clinical Ophthalmology, 2026.
Warning: These citations may not always be 100% accurate.